Literature DB >> 17724997

Pertussis epidemiology in Australia over the decade 1995-2005--trends by region and age group.

Helen E Quinn1, Peter B McIntyre.   

Abstract

Important changes have occurred in the National Immunisation Program for pertussis during the decade 1995-2005, including the introduction of acellular pertussis vaccine for all doses, removal from the schedule of the booster dose at 18 months, and the introduction of a booster dose for adolescents. In addition, the coverage of pertussis vaccine at 12 and 24 months has substantially increased as recorded by Australian Bureau of Statistics surveys and the Australian Childhood Immunisation Register. There were 75,458 notifications nationally between 1995 and 2005, with little change in the annual number of notifications at the national level but with periodic and dramatic changes in the age distribution of notified cases. Pertussis is well controlled in the 1-4 and 5-9 year age groups, and the highest annual notification rates continue to be in infants under 6 months of age. Adolescents aged 10-19 years had high notification rates in all states and territories, over this period, but 63% of notifications are now in the 20-59 year age range. Following the introduction of a fifth dose for adolescents, the current focus should be on protecting infants too young to be vaccinated and further defining the true morbidity of the disease in the elderly population.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17724997

Source DB:  PubMed          Journal:  Commun Dis Intell Q Rep        ISSN: 1447-4514


  31 in total

1.  Recent findings on pertussis epidemiology in Turkey.

Authors:  D Dilli; I Bostanci; Y Dallar; T Buzgan; H Irmak; M A Torunoğlu
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2008-01-09       Impact factor: 3.267

2.  The impact of adolescent pertussis immunization, 2004-2009: lessons from Australia.

Authors:  Helen E Quinn; Peter B McIntyre
Journal:  Bull World Health Organ       Date:  2011-07-05       Impact factor: 9.408

3.  Serum microRNA expression profile as a biomarker for the diagnosis of pertussis.

Authors:  Yiyue Ge; Kangchen Zhao; Yuhua Qi; Xiaoyan Min; Zhiyang Shi; Xian Qi; Yunfeng Shan; Lan Cui; Minghao Zhou; Yong Wang; Hua Wang; Lunbiao Cui
Journal:  Mol Biol Rep       Date:  2012-10-18       Impact factor: 2.316

4.  Different effects of whole-cell and acellular vaccines on Bordetella transmission.

Authors:  William E Smallridge; Olivier Y Rolin; Nathan T Jacobs; Eric T Harvill
Journal:  J Infect Dis       Date:  2014-01-16       Impact factor: 5.226

5.  Prospective evaluation of an Australian pertussis toxin IgG and IgA enzyme immunoassay.

Authors:  Meryta L May; Suhail A Doi; David King; Jenny Evans; Jennifer M Robson
Journal:  Clin Vaccine Immunol       Date:  2011-11-30

6.  Nonhuman primate model of pertussis.

Authors:  Jason M Warfel; Joel Beren; Vanessa K Kelly; Gloria Lee; Tod J Merkel
Journal:  Infect Immun       Date:  2012-01-17       Impact factor: 3.441

Review 7.  Symptomatic treatment of the cough in whooping cough.

Authors:  Kay Wang; Silvana Bettiol; Matthew J Thompson; Nia W Roberts; Rafael Perera; Carl J Heneghan; Anthony Harnden
Journal:  Cochrane Database Syst Rev       Date:  2014-09-22

8.  Can vaccine legacy explain the British pertussis resurgence?

Authors:  Maria A Riolo; Aaron A King; Pejman Rohani
Journal:  Vaccine       Date:  2013-10-16       Impact factor: 3.641

9.  Acellular pertussis vaccines protect against disease but fail to prevent infection and transmission in a nonhuman primate model.

Authors:  Jason M Warfel; Lindsey I Zimmerman; Tod J Merkel
Journal:  Proc Natl Acad Sci U S A       Date:  2013-11-25       Impact factor: 11.205

10.  Changes in the genomic content of circulating Bordetella pertussis strains isolated from the Netherlands, Sweden, Japan and Australia: adaptive evolution or drift?

Authors:  Audrey J King; Tamara van Gorkom; Han G J van der Heide; Abdolreza Advani; Saskia van der Lee
Journal:  BMC Genomics       Date:  2010-01-26       Impact factor: 3.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.